Epocrates vs UpToDate: what each costs and what each is good at

Epocrates, and it is not close. Epocrates+ lists at $179.99 a year (or $24.99 monthly) as of August 2026, and it publishes that figure openly. Wolters Kluwer publishes no individual UpToDate price at all, quoting it only after you select a country and a professional role, and the annual figures circulating on software directory sites are not vendor-published and disagree with each other. What you can say with confidence is that UpToDate sits well above Epocrates for an individual buyer, which for a clinician paying out of pocket is the first thing that gets noticed.

The price gap makes sense once you see what you are buying. Epocrates sells you a fast, well-maintained drug reference. UpToDate sells you an editorial operation: thousands of physician authors writing, updating and grading topic reviews. Whether that is worth the difference depends entirely on whether your day is full of drug lookups or clinical questions. Before paying for either, check your hospital or medical library, because institutional licences are common and a lot of clinicians pay twice without realizing it.

Not for the job UpToDate does. Epocrates answers what this drug is, what it interacts with and how it is dosed. UpToDate answers how to manage this condition, with the reasoning and the grade attached. If you tried to run a complex management decision off a drug reference, you would be missing the argument, not just the detail.

The reverse is also true, and clinicians feel it more often: UpToDate is a slow way to check one dose. That is why plenty of prescribers keep a cheap drug reference on the phone and a deeper reference on the desk, and why the two subscriptions coexist rather than compete.

Both tools wait to be asked. To catch a problem with the script in front of you, you have to think to check the interaction, then think to check the contraindication, then think to check the renal dose, then think about whether a different agent would be safer. Four questions, four lookups, on an afternoon that is already running behind. The checks that get skipped are the ones nobody thought to run.

Prescriber.io turns that into one step. Enter the drug or the scenario and it checks interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments and suggests guideline-based alternatives, in a single card with cited sources. It is decision-support for licensed clinicians, not autonomous prescribing: you review every flag, verify against official sources, and sign.

For learning a condition end to end, UpToDate is the stronger tool, and that is exactly why medical schools and residency programs license it. A topic review walks you through the reasoning, names the author, and grades the strength of each recommendation, so you are absorbing how the conclusion was reached rather than memorizing the conclusion. Epocrates gives you the fact without the argument, which is efficient on the wards and thin as a study resource.

The cost calculus is also different for trainees. Wolters Kluwer prices UpToDate lower for residents and students than the standard individual rate, which is why the store asks for your professional role before quoting anything, and most students already have access through their institution, so the practical comparison for a trainee is usually free UpToDate through the school against a free Epocrates tier on the phone. Keeping both is common and costs nothing. If you are paying personally after training ends, that is when the up to date vs Epocrates decision becomes real, and it usually resolves on whether your daily questions are about conditions or about drugs.

Start with the thing neither product is: neither Epocrates nor UpToDate issues clinical guidelines. Guidelines are published by specialty societies and expert panels, groups such as the American College of Cardiology, the Infectious Diseases Society of America and the American Diabetes Association, and both products are downstream of that work. What you are really choosing between is two different ways of packaging somebody else's guideline.

UpToDate is much the closer of the two to a guideline experience. A topic review sets out the reasoning, names the authors, grades the strength of each recommendation and cites the society guidance it is drawing on, so you can see which recommendations rest on strong evidence and which are expert consensus. That grading is the part that matters for anyone learning to read guidance critically, because it makes the uncertainty visible instead of flattening everything into one confident instruction.

Epocrates works the other way round. It is built to hand you a fact in seconds, and the paid epocrates+ tier adds a disease reference on top of the drug content. What it does not give you is the argument behind the recommendation or a graded view of how solid it is. That is a reasonable trade on the wards, where you often need the number and not the debate, and a poor one when the point of the exercise is to understand why the recommendation exists.

For a medical university setting specifically, there is a further step worth insisting on: read the actual guideline. Both of these are tertiary sources that summarize and interpret, and a student who can trace a recommendation from a topic review back to the society document that produced it is doing the thing the training is for. Use UpToDate to find the recommendation and understand its grade, then follow the citation to the source. Almost every US medical school already licenses UpToDate through its library, so this usually costs a student nothing, and our page on getting UpToDate access through a medical library covers how to check.

UpToDate and Epocrates are not the same category, which is why this comparison so often ends in "keep both". If what you actually need to settle is which drug reference to pay for, the sharper comparison is Epocrates against the pharmacy-grade option, and we run that head to head in Epocrates vs Lexicomp, now sold as UpToDate Lexidrug. It is the same vendor as UpToDate, and the drug content inside UpToDate comes from it.

The published numbers make the shape of the decision clear, and so does the one that is missing. Epocrates+ lists at $179.99 a year and the Lexidrug personal subscription at $29.99 a month, while Wolters Kluwer publishes no individual UpToDate price at all. We break each one down in our guides to Epocrates cost, Lexicomp cost and UpToDate cost, including the check that saves most clinicians the most money, which is finding out what their employer already licenses.